The Association of the Cholesterol Efflux Capacity with the <i>Paraoxonase 1</i> Q192R Genotype and the Paraoxonase Activity
-
- Oniki Kentaro
- Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Ohura Kayoko
- Graduate School of Pharmaceutical Sciences, Kumamoto University Headquarters for Admissions and Education, Kumamoto University
-
- Endo Megumi
- Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Akatwijuka Daniel
- Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Matsumoto Erika
- Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Nakamura Teruya
- Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Ogata Yasuhiro
- Japanese Red Cross Kumamoto Health Care Center
-
- Yoshida Minoru
- Japanese Red Cross Kumamoto Health Care Center
-
- Harada-Shiba Mariko
- Cardiovascular Center, Osaka Medical and Pharmaceutical University Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute
-
- Saruwatari Junji
- Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Ogura Masatsune
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University
-
- Imai Teruko
- Graduate School of Pharmaceutical Sciences, Kumamoto University Daiichi University of Pharmacy
抄録
<p> Aims: Paraoxonase 1 (PON1) binds to high-density lipoprotein (HDL) and protects against atherosclerosis. However, the relationship between functional PON1 Q192R polymorphism, which is associated with the hydrolysis of paraoxon (POXase activity) and atherosclerotic cardiovascular disease (ASCVD), remains controversial. As the effect of PON1 Q192R polymorphism on the HDL function is unclear, we investigated the relationship between this polymorphism and the cholesterol efflux capacity (CEC), one of the biological functions of HDL, in association with the PON1 activity.</p><p>Methods: The relationship between PON1 Q192R polymorphisms and CEC was investigated retrospectively in 150 subjects without ASCVD (50 with the PON1 Q/Q genotype, 50 with the Q/R genotype, and 50 with the R/R genotype) who participated in a health screening program. The POXase and arylesterase (AREase: hydrolysis of aromatic esters) activities were used as measures of the PON1 activity.</p><p>Results: The AREase activity was positively correlated with CEC independent of the HDL cholesterol levels. When stratified by the PON1 Q192R genotype, the POXase activity was also positively correlated with CEC independent of HDL cholesterol. PON1 Q192R R/R genotype carriers had a lower CEC than Q/Q or Q/R genotype carriers, despite having a higher POXase activity. Moreover, in a multiple regression analysis, the PON1 Q192R genotype was associated with the degree of CEC, independent of the HDL cholesterol and POXase activity.</p><p>Conclusions: The PON1 Q192R R allele is associated with reduced CEC in Japanese people without ASCVD. Further studies on the impact of this association on the severity of atherosclerosis and ASCVD development are thus called for.</p>
収録刊行物
-
- Journal of Atherosclerosis and Thrombosis
-
Journal of Atherosclerosis and Thrombosis advpub (0), 2024
一般社団法人 日本動脈硬化学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390862467736453376
-
- ISSN
- 18803873
- 13403478
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
-
- 抄録ライセンスフラグ
- 使用不可